Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P62805: Variant p.Glu64Gln

Histone H4
Gene: H4C16
Feedback?
Variant information Variant position: help 64 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glutamate (E) to Glutamine (Q) at position 64 (E64Q, p.Glu64Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (E) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In a breast cancer sample; somatic mutation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 64 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 103 The length of the canonical sequence.
Location on the sequence: help VKRISGLIYEETRGVLKVFL E NVIRDAVTYTEHAKRKTVTA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         VKRISGLIYEETRGVLKVFLENVIRDAVTYTEHAKRKTVTA

Mouse                         VKRISGLIYEETRGVLKVFLENVIRDAVTYTEHAKRKTVTA

Rat                           VKRISGLIYEETRGVLKVFLENVIRDAVTYTEHAKRKTVTA

Pig                           VKRISGLIYEETRGVLKVFLENVIRDAVTYTEHAKRKTVTA

Bovine                        VKRISGLIYEETRGVLKVFLENVIRDAVTYTEHAKRKTVTA

Chicken                       VKRISGLIYEETRGVLKVFLENVIRDAVTYTEHAKRKTVTA

Xenopus laevis                VKRISGLIYEETRGVLKVFLENVIRDAVTYTEHAKRKTVTA

Xenopus tropicalis            VKRISGLIYEETRGVLKVFLENVIRDAVTYTEHAKRKTVTA

Caenorhabditis elegans        VKRISGLIYEETRGVLKVFLENVIRDAVTYCEHAKRKTVTA

Drosophila                    VKRISGLIYEETRGVLKVFLENVIRDAVTYTEHAKRKTVTA

Slime mold                    VKRISFPIYEETRNVLRTFLTNVIRDSVAYTEHAGRRTVTA

Baker's yeast                 VKRISGLIYEEVRAVLKSFLESVIRDSVTYTEHAKRKTVTS

Fission yeast                 VKRISALVYEETRAVLKLFLENVIRDAVTYTEHAKRKTVTS

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 103 Histone H4
Modified residue 45 – 45 N6-(2-hydroxyisobutyryl)lysine; alternate
Modified residue 45 – 45 N6-butyryllysine; alternate
Modified residue 45 – 45 N6-propionyllysine; alternate
Modified residue 48 – 48 Phosphoserine; by PAK2
Modified residue 52 – 52 Phosphotyrosine
Modified residue 60 – 60 N6-(2-hydroxyisobutyryl)lysine; alternate
Modified residue 60 – 60 N6-glutaryllysine; alternate
Modified residue 78 – 78 N6-(2-hydroxyisobutyryl)lysine; alternate
Modified residue 78 – 78 N6-(beta-hydroxybutyryl)lysine; alternate
Modified residue 78 – 78 N6-butyryllysine; alternate
Modified residue 78 – 78 N6-glutaryllysine; alternate
Modified residue 78 – 78 N6-lactoyllysine; alternate
Modified residue 78 – 78 N6-propionyllysine; alternate
Modified residue 78 – 78 N6-succinyllysine; alternate
Modified residue 80 – 80 N6-(2-hydroxyisobutyryl)lysine; alternate
Modified residue 80 – 80 N6-butyryllysine; alternate
Modified residue 80 – 80 N6-glutaryllysine; alternate
Modified residue 80 – 80 N6-propionyllysine; alternate
Modified residue 80 – 80 N6-succinyllysine; alternate
Modified residue 81 – 81 Phosphothreonine
Cross 60 – 60 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate
Cross 80 – 80 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate
Helix 51 – 76



Literature citations
The consensus coding sequences of human breast and colorectal cancers.
Sjoeblom T.; Jones S.; Wood L.D.; Parsons D.W.; Lin J.; Barber T.D.; Mandelker D.; Leary R.J.; Ptak J.; Silliman N.; Szabo S.; Buckhaults P.; Farrell C.; Meeh P.; Markowitz S.D.; Willis J.; Dawson D.; Willson J.K.V.; Gazdar A.F.; Hartigan J.; Wu L.; Liu C.; Parmigiani G.; Park B.H.; Bachman K.E.; Papadopoulos N.; Vogelstein B.; Kinzler K.W.; Velculescu V.E.;
Science 314:268-274(2006)
Cited for: VARIANT [LARGE SCALE ANALYSIS] GLN-64;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.